Asia Pacific Organoids Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The Asia Pacific organoids market is projected to grow significantly, reaching approximately US$ 2,327.10 million by 2031, up from US$ 419.14 million in 2023, with a remarkable compound annual growth rate (CAGR) of 23.9% during the forecast period.

Executive Summary and Market Analysis

The organoids market in the Asia Pacific region includes countries such as Australia, China, India, Japan, South Korea, and others. The market is expected to expand rapidly due to several factors, including the rising incidence of cancer, increased demand for research on gene mutations and cancer, government initiatives to promote awareness of human organoids, supportive regulations for the development and commercialization of advanced organoid products, and heightened funding for organoid research.

Market Segmentation Analysis

The Asia Pacific organoids market can be segmented based on type, application, source, offering, and method:

Type: The market is divided into organoids from the intestine, liver, stomach, pancreas, lung, brain, kidney, and others. In 2023, the intestine organoid segment held the largest market share.
Application: Key applications include developmental biology disease, infectious disease pathology, regenerative medicine, drug toxicity and efficacy testing, drug discovery, and personalized medicine. The developmental biology disease segment was the largest in 2023.
Source: The market is categorized into pluripotent stem cells and organ-specific adult stem cells, with pluripotent stem cells dominating the market share in 2023.
Offering: This segment includes instruments, consumables, and services, with consumables leading the market in 2023. Instruments are further divided into devices and equipment, while consumables include sensors and other items.
Method: The methods used in organoid development include micropatterned plates, ultralow attachment plates, hanging drop, microdroplet or emulsion, and others, with the hanging drop method holding the largest share in 2023.

Market Outlook

Personalized medicine, or precision medicine, is a growing trend that tailors medical treatments to individual patients based on their specific responses or disease risks. This trend is significantly driving the development and application of organoid technologies across Asia. For instance, in China, ACCURATE International Biotechnology has created one of the largest tumor organoid platforms globally, featuring over 5,000 models for patient-specific drug testing. Collaborations with institutions like the University of Macau have further advanced research in disease modeling and drug responses.
In Japan, universities such as Kyushu and Nagoya are integrating artificial intelligence with organoid development, achieving high accuracy in selecting quality organoids for therapeutic applications. Researchers are also exploring gene-edited organoids to investigate liver and neurological disorders. South Korea's 2024 Organoid Developer Conference highlighted regenerative medicine applications, with experts discussing organoid use in treating conditions like ulcerative colitis. Singapore is emerging as a hub for innovation, exemplified by Next&Bio's partnership with the Cancer Science Institute of Singapore to develop a cancer organoid bank for more effective oncology therapies.

Pharmacists are crucial in promoting personalized medicine, raising awareness about precision treatments, and encouraging pharmaceutical companies to create tailored therapies. Personalized cancer medicine focuses on developing effective treatment strategies based on the genomic profiles of tumors. The demand for research in personalized tumor modeling is increasing, as tumor organoids can accurately predict drug responses, offering significant advantages over traditional models.

Country Insights

The Asia Pacific organoids market includes key countries such as Japan, China, India, South Korea, Australia, and Southeast Asia, with China holding the largest market share in 2023. The growth in China is driven by advancements in research and the popularity of personalized medicine. The development of tumor organoids has been a significant breakthrough, allowing researchers to study various tissues and organs affected by tumors.

Collaborations, such as the one between Hubrecht Organoid Technology and BGI-Qingdao, aim to enhance personalized care and treatment development in China. Additionally, increasing funding for stem cell research is expected to boost organoid research and development.

Company Profiles

Key players in the organoids market include STEMCELL Technologies Inc., Molecular Devices, Hubrecht Organoid Technology, Definigen, Organoid Therapeutics, Thermo Fisher Scientific, Corning, Merck KGaA, InSphero, ACRO Biosystems, Bio-Techne, SUN bioscience, ORGANOID SCIENCES, Crown Bioscience, Sartorius, 3D Biotek, Prellis Biologics, 3Dnamics, and Cellesce. These companies are employing strategies such as expansion, product innovation, and mergers to enhance their market presence and offer innovative solutions.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific organoids market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific organoids market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the organoids market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution. Show more